These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 29157960)

  • 1. Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group.
    Boonnak K; Dhitavat J; Thantamnu N; Kosoltanapiwat N; Auayporn M; Jiang L; Puthavathana P; Pitisuttithum P
    Vaccine; 2017 Dec; 35(52):7339-7346. PubMed ID: 29157960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
    Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
    Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.
    Frenck RW; Belshe R; Brady RC; Winokur PL; Campbell JD; Treanor J; Hay CM; Dekker CL; Walter EB; Cate TR; Edwards KM; Hill H; Wolff M; Leduc T; Tornieporth N
    Vaccine; 2011 Aug; 29(34):5666-74. PubMed ID: 21699951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults.
    Ansaldi F; Valle L; de Florentiis D; Parodi V; Murdaca G; Bruzzone B; Durando P; Setti M; Icardi G
    Hum Vaccin Immunother; 2012 Aug; 8(8):1048-52. PubMed ID: 22832261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain.
    Hung IF; Levin Y; To KK; Chan KH; Zhang AJ; Li P; Li C; Xu T; Wong TY; Yuen KY
    Vaccine; 2012 Oct; 30(45):6427-35. PubMed ID: 22910287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
    Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
    Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
    Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.
    Ansaldi F; Canepa P; Ceravolo A; Valle L; de Florentiis D; Oomen R; Vogel FR; Denis M; Samson SI; Icardi G
    Vaccine; 2012 Apr; 30(18):2908-13. PubMed ID: 22342501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of influenza vaccine among HIV-infected adults: Conventional vaccine vs. intradermal vaccine.
    Seo YB; Lee J; Song JY; Choi HJ; Cheong HJ; Kim WJ
    Hum Vaccin Immunother; 2016; 12(2):478-84. PubMed ID: 26431466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.
    Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli C; Groth N; Levin Y; Del Giudice G
    Hum Vaccin Immunother; 2014; 10(6):1701-10. PubMed ID: 24732325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
    Hung IF; Zhang AJ; To KK; Chan JF; Li P; Wong TL; Zhang R; Chan TC; Chan BC; Wai HH; Chan LW; Fong HP; Hui RK; Kong KL; Leung AC; Ngan AH; Tsang LW; Yeung AP; Yiu GC; Yung W; Lau JY; Chen H; Chan KH; Yuen KY
    Lancet Infect Dis; 2016 Feb; 16(2):209-18. PubMed ID: 26559482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.
    Gorse GJ; Falsey AR; Johnson CM; Morrison D; Fried DL; Ervin JE; Greenberg DP; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2013 Dec; 31(50):6034-40. PubMed ID: 24055306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic.
    Chuaychoo B; Kositanont U; Rittayamai N; Niyomthong P; Songserm T; Maranetra KN; Rattanasaengloet K; Nana A
    Hum Vaccin Immunother; 2016 Jul; 12(7):1728-37. PubMed ID: 27153158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody responses after dose-sparing intradermal influenza vaccination.
    Auewarakul P; Kositanont U; Sornsathapornkul P; Tothong P; Kanyok R; Thongcharoen P
    Vaccine; 2007 Jan; 25(4):659-63. PubMed ID: 17011678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand.
    Garg S; Thongcharoen P; Praphasiri P; Chitwarakorn A; Sathirapanya P; Fernandez S; Rungrojcharoenkit K; Chonwattana W; Mock PA; Sukwicha W; Katz JM; Widdowson MA; Curlin ME; Gibbons RV; Holtz TH; Dawood FS; Olsen SJ
    Clin Infect Dis; 2016 Feb; 62(3):383-391. PubMed ID: 26486702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunogenicity of intradermal influenza vaccination in COPD patients.
    Chuaychoo B; Wongsurakiat P; Nana A; Kositanont U; Maranetra KN
    Vaccine; 2010 May; 28(24):4045-51. PubMed ID: 20412877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
    Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
    PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
    Narang V; Lu Y; Tan C; Camous XFN; Nyunt SZ; Carre C; Mok EWH; Wong G; Maurer-Stroh S; Abel B; Burdin N; Poidinger M; Tambyah PA; Bosco N; Visan L; Ng TP; Larbi A
    Front Immunol; 2018; 9():2465. PubMed ID: 30405641
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy.
    Ottóffy G; Horváth P; Muth L; Sólyom A; Garami M; Kovács G; Nyári T; Molnár D; Pauler G; Jankovics I
    Pediatr Blood Cancer; 2014 Jun; 61(6):1013-6. PubMed ID: 24395342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.